Table 2.
Distribution of mCRPC cohorts based on age at time of first mCRPC drug usage
| Commercial Claims Database | |||||
|---|---|---|---|---|---|
| Total prostate cancer Populationa | Total evaluable mCRPC Patientsb | mCRPC Cohortb , c | |||
| 2000–2003 | 2004–2008 | 2009–2013 | |||
| n | 326,907d | 3437e | 175 | 1124 | 2138 |
| Age, years | |||||
| Median (interquartile range) | 64.0 (59–74) | 70.0 (62–78) | 69.0 (61–77) | 71.0 (61–78) | 70.0 (62–78) |
| Age group, n (%) | |||||
| 44–64 years | 164,499 (50.3) | 1215 (35) | 65 (37) | 391 (35) | 759 (36) |
| 65–80 years | 123,658 (37.8) | 1604 (47) | 86 (49) | 547 (49) | 971 (45) |
| >80 years | 33,093 (10.1) | 604 (18) | 22 (13) | 180 (16) | 402 (19) |
mCRPC, metastatic castration‐resistant prostate cancer.
a
Age at time of first prostate cancer diagnosis.
b
Based on age at time of first mCRPC drug usage.
c
14 patients were not included in the age group splits due to inconsistency or missing values in their date‐of‐birth data.
d
Data for 5657 patients were not included due to inconsistency in date‐of‐birth data.
e
227 patients who had only 1 mCRPC injectable claim in the database were not deemed evaluable.